Who makes Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost?

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost is developed by Innovative Medical.

What development phase is Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost in?

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost is FDA-approved (marketed).

Last reviewed 2026-05-13 · How we verify

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost

Innovative Medical · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost
Sponsor	Innovative Medical
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost CI brief — competitive landscape report
Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost updates RSS · CI watch RSS
Innovative Medical portfolio CI